New Brunswick, N.J. (July 18, 2017) – Johnson & Johnson (NYSE: JNJ) today announced sales of $18.8 billion for the second quarter of 2017, an increase of 1.9% as compared to the second quarter of 2016. Operational sales results increased 2.9% and the negative impact of currency was 1.0%. Domestic sales increased 1.6%. International sales increased 2.3%, reflecting operational growth of 4.4% and a negative currency impact of 2.1%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 0.5%, domestic sales decreased 1.0% and international sales increased 2.0%.*
Cardinal Health has concluded the purchase of Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency business from Medtronic for a total of $6.1bn.
Sanofi is to buy private US vaccines biotech Protein Sciences in a deal valued at up to $750 million, in a move to bolster its vaccines portfolio.
As the most potential market in china, Hemodialysis market appears a large revenue space. With the opening of private hemodialysis services, private economy in the hemodialysis industry is about to take a ”Golden era”.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.